Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
Rhea-AI Summary
Structure Therapeutics (NASDAQ: GPCR) will release topline data from its ACCESS clinical program of aleniglipron, a once-daily oral small-molecule GLP-1 receptor agonist for obesity, before market open on Monday, December 8, 2025. Management will host a conference call and webcast to discuss the data at 8:30 a.m. ET the same day.
Investors can access the live webcast via the company Investor Relations events page and obtain phone dial-in details from the provided link. A replay will be posted approximately two hours after the live event and will remain available for 90 days.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
GPCR gained 5.21% while close peers showed mixed, smaller moves (e.g., ELVN +1.77%, NUVB +2.64%, PGEN -5.01%). No broad sector trend is evident, suggesting today’s strength is company-specific into the ACCESS data release.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Earnings update | Positive | +3.9% | Reaffirmed ACCESS data timing and strong cash balance through at least 2027. |
| Sep 02 | Investor conferences | Positive | +4.0% | Announced participation in major healthcare investor conferences with webcasts. |
| Aug 06 | Earnings update | Negative | -0.7% | Higher R&D spend and larger net loss while advancing oral obesity pipeline. |
| Jun 20 | Clinical data | Positive | +1.7% | New preclinical data for oral amylin agonist and GLP-1 candidate at ADA meeting. |
Across recent earnings, conference, and clinical updates, GPCR’s share price has consistently moved in the same direction as the apparent news tone, with no recorded divergences.
This announcement fits into a sequence of catalyst-focused updates for aleniglipron and the obesity portfolio. On Aug 06, 2025 and Nov 06, 2025, earnings reports highlighted strong cash positions of $786.5M and $799.0M and reaffirmed plans for ACCESS topline data by year-end 2025. A Jun 20, 2025 clinical update showcased positive preclinical data for ACCG-2671 and GSBR-5595, while a Sep 02, 2025 conference notice underscored growing investor outreach. Today’s scheduling of the ACCESS topline readout is the next step in that clearly signposted catalyst path.
Regulatory & Risk Context
The company has an effective S-3ASR shelf registration dated 2025-08-06, expiring 2028-08-06, with 0 recorded uses so far. This structure provides flexibility to raise capital in the future without specifying any current dollar capacity in this dataset.
Market Pulse Summary
This announcement sets a clear timetable for the pivotal ACCESS topline data for oral GLP-1 agonist aleniglipron, with results scheduled before market open on December 8, 2025 and a management call at 8:30 a.m. ET. It follows prior guidance from 2025 earnings updates that highlighted strong cash balances and year-end readout plans. Investors may track how results fit within the obesity pipeline narrative and monitor any subsequent financing or development decisions disclosed after the data.
AI-generated analysis. Not financial advice.
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced plans to release topline data from its ACCESS clinical program of aleniglipron, the company’s once-daily oral small molecule GLP-1 receptor agonist for the treatment of obesity, before the market opens on Monday, December 8, 2025. Members of management will host a conference call and webcast to discuss the data at 8:30 a.m. ET the same day.
To access the live webcast, please visit the Investor Relations page of the company’s website at https://ir.structuretx.com/events-presentations/events. To access the call by phone, participants should visit this link to receive dial-in details. The webcast will be made available for replay on the company's website beginning approximately two hours after the live event. The replay of the webcast will be available for 90 days.
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.
Investors:
Danielle Keatley
Structure Therapeutics Inc.
ir@structuretx.com
Media:
Dan Budwick
1AB
Dan@1abmedia.com
FAQ
When will Structure Therapeutics (GPCR) release topline ACCESS data?
What time is the Structure Therapeutics (GPCR) conference call and webcast on December 8, 2025?
How can investors access the live webcast for Structure Therapeutics (GPCR)?
When will the replay of the Structure Therapeutics (GPCR) webcast be available and for how long?
What is aleniglipron in Structure Therapeutics (GPCR)'s pipeline?
How do I get phone dial-in details for the Structure Therapeutics (GPCR) December 8 call?
